Three internal programs at different design stages. The figures below are in-silico predictions and design targets — wet-lab validation is scheduled, not yet complete, and is labelled as such throughout. First external case studies publish as partnerships close; partner names stay redacted until each one signs off on public disclosure.
A senolytic bispecific against a carbohydrate target.
The hardest of the three programs — GD3 ganglioside is a glycan epitope, not a protein domain, so conventional binder libraries struggle. We applied a CVaR-VQE active-space correction to the binding pose and combined a quantum-corrected GD3 binder (MOD-0881) with a survival-pathway-gating second arm. Lead candidate CAND-P3-LEAD-08 came out of the rank pass at a predicted 42 pM Kd; SPR and ADCC validation are scheduled, not yet run. Senolytic mechanism per Iltis et al., Nat Aging 2024.
A trispecific TCE with conditional costimulation.
CLDN18.2 tumor restriction × attenuated CD3 × 4-1BB conditional agonism. The third arm is a costimulation gate that only triggers in the tumor microenvironment, designed to address the exhaustion phenotype seen with classical CD3 bispecifics. Lead candidate CAND-P1-LEAD-04 assembled from MOD-0492 + MOD-0617 + MOD-0744 with stabilized G4S linkers.
Wet-lab status
Scheduled Q3 '26
A BBB shuttle that tunes for kinetics.
TfR1 (low-affinity, transcytosis-optimized) × IGF-1R (capacity-additive). The TfR1 arm is deliberately weak-binding to avoid receptor sequestration; the IGF-1R adds a parallel route to increase BBB-crossing capacity without compromising selectivity. Target brain exposure >3% — roughly 30× the industry standard of 0.1% — to be confirmed in the Q3 '26 in-vivo study. Cargo-agnostic: any CNS-restricted biologic can be fused to the shuttle scaffold.
Predicted Kd (TfR1)
2.4 nM
External case studies · publishing as partners sign off
The next three case-study slots are reserved for external partnerships. Public disclosure follows the partner's own announcement schedule.
Partner 1
TBD · 2026 Q3
Partner 2
TBD · 2026 Q4
Partner 3
TBD · 2027 Q1